在转移性脏癌症中,常见的 (生物) 标志物
1Département d'Oncologie Médicale, Centre Antoine Lacassagne, Université Côte d'Azur, Nice.
Bulletin du cancer
|June 30, 2024
概括
常规生物标志物对于治疗转移性细胞癌 (mRCC) 是至关重要的. 本研究审查了当前和新兴的生物标志物,以改善mRCC患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 转移性细胞癌 (mRCC) 是一种复杂的疾病.
- 准确的预后和预测标记对于治疗决策至关重要.
研究的目的:
- 审查转移性细胞癌的既定和新生物标志物.
- 讨论这些生物标志物在患者管理中的临床实用性.
主要方法:
- 关于mRCC中的生物标志物研究的文献综述.
- 分析当前的临床指南和研究趋势.
主要成果:
- 已经确立的生物标志物,如恒标准,被广泛使用.
- 新兴的生物标志物显示出个性化治疗的前景.
结论:
- 生物标志物引导治疗是改善mRCC结果的关键.
- 需要持续的研究来验证新的生物标志物.
更多相关视频
相关概念视频
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...